GlassScriptPhysician profile
Rebecca A Brown
NPI 1245414234
$7,520.22
in general payments reported to CMS, 2019-2025
39 companies · $1,522 in 2025
The $1,522 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,336 · 2022: $2,073 · 2023: $1,065 · 2024: $1,525 · 2025: $1,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,937 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,937.48 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,355.00 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $836.94 | 2021-2025 | |
| Novo Nordisk INC | $661.91 | 2021-2025 | Wegovy, Saxenda |
| Astellas Pharma US INC | $411.52 | 2021-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $380.07 | 2023-2025 | Xifaxan, Trulance |
| Pfizer INC. | $358.18 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $301.48 | 2022 | |
| Exeltis, USA INC. | $290.84 | 2021-2025 | Slynd |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $288.44 | 2025 | Caplyta |
| Therapeuticsmd, INC. | $256.51 | 2021-2022 | |
| Ascend Therapeutics US, LLC | $245.03 | 2022-2023 | |
| Lilly USA, LLC | $243.34 | 2023-2024 | Zepbound, Emgality |
| Avion Pharmaceuticals | $223.10 | 2021-2022 | |
| Corcept Therapeutics | $203.74 | 2024-2025 | Korlym |
| Millicent US INC | $180.11 | 2024-2025 | Femlyv, Intrarosa, Femring |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $160.44 | 2024 | |
| Mycovia Pharmaceuticals, INC. | $122.87 | 2022-2023 | Vivjoa |
| Sumitomo Pharma America, INC. | $115.58 | 2023-2025 | Myfembree |
| Hologic Sales and Service, LLC | $100.40 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Myovant Sciences INC. | $86.82 | 2021-2022 | |
| Intra-Sana Laboratories | $72.85 | 2024-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Bausch Health US, LLC | $70.73 | 2022 | |
| Scynexis, INC. | $70.41 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.38 | 2025 | |
| Supernus Pharmaceuticals, INC. | $68.57 | 2021-2022 | |
| Sage Therapeutics, LLC | $57.84 | 2025 | Zurzuvae |
| Biohaven Pharmaceuticals, INC. | $43.19 | 2021 | |
| Daiichi Sankyo INC. | $31.73 | 2021-2022 | |
| Celltrion USA INC. | $29.23 | 2024 | Zymfentra |
| Ardelyx, INC. | $28.63 | 2025 | Ibsrela |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Dysis Medical, INC. | $21.84 | 2021 | |
| Lupin INC. | $19.25 | 2021 | |
| Amgen INC. | $17.71 | 2024 | Evenity, Prolia |
| Axsome Therapeutics, INC. | $16.62 | 2025 | Auvelity |
| Eisai INC. | $14.74 | 2021 | |
| Exact Sciences Corporation | $14.42 | 2024 | Cologuard Collection Kit |
| Agile Therapeutics, INC. | $13.74 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.